Trifluoperazine — Medical Description

Trifluoperazine is a first-generation (typical) antipsychotic belonging to the phenothiazine class. It is a relatively high-potency dopamine D₂-receptor antagonist that reduces excessive dopaminergic activity in the brain. It is primarily used in the treatment of schizophrenia and, in some settings, for the short-term management of severe anxiety.

Medical Uses

• Schizophrenia: Helps control psychotic symptoms such as hallucinations, delusions, disorganized thinking, and abnormal behavior.
• Severe anxiety: Trifluoperazine may be prescribed for anxiety when considered appropriate by a physician; because of its potential for serious adverse effects, it is generally not preferred for routine or mild anxiety.

Mechanism of Action

Trifluoperazine primarily blocks dopamine D₂ receptors in the central nervous system. Reduction of excessive dopamine signaling contributes to its antipsychotic effects. As a high-potency first-generation antipsychotic, it has a comparatively greater tendency to cause extrapyramidal motor adverse effects than many lower-potency antipsychotics.

Common & Important Adverse Effects

Potential adverse effects include:

• Extrapyramidal symptoms: dystonia, akathisia, tremor, rigidity and other abnormal movements.
• Tardive dyskinesia: potentially persistent involuntary movements, particularly with prolonged treatment.
• Drowsiness, dizziness and impaired coordination.
• Dry mouth, blurred vision and other anticholinergic effects.
• Orthostatic hypotension.
• Increased prolactin levels and associated endocrine effects.
• Less commonly, neuroleptic malignant syndrome (NMS), seizures, blood-cell abnormalities and other serious reactions.

Important Warnings & Precautions

Trifluoperazine should be used under medical supervision. Particular caution is required in patients with seizure disorders, cardiovascular disease, glaucoma, liver disease, blood-cell disorders, or other conditions that may increase the risk of adverse effects.

Antipsychotic medications, including trifluoperazine, are associated with an increased risk of death in elderly patients with dementia-related psychosis and are not approved for this indication.

Patients should seek urgent medical attention for symptoms suggestive of NMS—such as high fever, severe muscle rigidity, confusion or marked changes in heart rate—as well as severe involuntary movements, seizures, difficulty swallowing or breathing, or other serious reactions.

Discontinuation

Trifluoperazine should not be stopped abruptly without medical advice. The prescribing clinician may gradually reduce the dose to minimize withdrawal or rebound symptoms.

Patient Disclaimer

This information is for educational purposes only and does not replace medical advice. Trifluoperazine is a prescription antipsychotic medication and should be used only under the supervision of a qualified healthcare professional. Do not start, stop, or change the dose without consulting your physician.

References

• MedlinePlus / U.S. National Library of Medicine (NIH) — Trifluoperazine Drug Information.
• NCBI Bookshelf / NIH — information on first-generation antipsychotics and dopamine receptor pharmacology.
• Merck Manual — Antipsychotic medications and adverse-effect profiles.
• PubChem / NIH — Trifluoperazine pharmacological and chemical information.

Note: Trifluoperazine is an older typical antipsychotic, and current treatment choices for schizophrenia often favor second-generation antipsychotics depending on the patient's clinical circumstances and adverse-effect profile.